Back to News List

Morningside ventures invests $54m in Immune Regulation, a GWC portfolio company

21 September 2020

Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies. (London UK and Boston USA, 21 September 2020) Immune Regulation Limited (“Immune Regulation”), a US and UK based clinical stage biotechnology company, today announced the closing of a Series B funding…